DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Asfotase alfa
Asfotase alfa
European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa As a Treatment for Patients with Hypophosphatasia
Asfotase Alfa for Infants and Young Children with Hypophosphatasia: 7 Year Outcomes of a Single-Arm, Open-Label, Phase 2 Extension Trial
Asfotase Alfa (Strensiq) for Treatment of Hypophosphatasia in Infants and Children
Transaction Drug 1St (DIN) 2Nd (PIN) 3Rd (PIN) 4Th (PIN) 5Th (PIN) 6Th
CHMP Agenda of the 10-13 October 2016 Meeting
New Drug Approvals and Extended Indications for Infants, Children, and Adolescents Marcia L
ENTRY WATCH 2016 Published by the Patented Medicine Prices Review Board June 2018 Meds Entry Watch, 2016 Is Available in Electronic Format on the PMPRB Website
Strensiq, INN-Asfotase Alfa
Asfotase Alfa (Strensiq) Reference Number: CP.PHAR.328 Effective Date: 03/17 Coding Implications Last Review Date: 03/17 Revision Log
Inventory of Community and National Incentive Measures to Aid The
Lists of Medicinal Products for Rare Diseases in Europe*
Strensiq, INN-Asfotase Alfa
Odontoblastic Differentiation of Dpscs
Pharmacy Medical Necessity Guidelines: Strensiq™ (Asfotase Alfa)
Lysosomal Storage Disorders
WO 2017/031114 Al 23 February 2017 (23.02.2017) P O P C T
Specialty Drug List
Colorado Medicaid Program
Top View
Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
Self-Administered Specialty Drug List
Alphabetical Listing by Therapeutic Category Dod UNIFORM
Aralast NP™, Glassia™, Prolastin®-C
Specialty Formulary
Specialty Pharmacy Program Drug List
Asfotase Alfa (Strensiq™) EOCCO POLICY
57 Orphan Drugs Approved by the EC Between 2012 and 2016 Were Found, of Which 40 (70.2%) Had Been Authorised in Spain
Premium Value
STRENSIQ Safely and Effectively
Procedures, Programs and Drugs You Must Precertify
State and Specialty Pharmacy Drug Reimbursement Rates
Partnerre Trigger Pharmaceuticals (At 2.6.20)
Health Plan Insights
Reimbursement Criteria for Frequently Requested Drugs
State and Specialty Pharmacy Drug Reimbursement Rates
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
Enzyme Related Therapies
State and Specialty Pharmacy Drug Reimbursement Rates
( 12 ) Patent Application Publication ( 10 ) Pub . No . : US 2018 / 0230445
New Brunswick Drug Plans Formulary
BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
Drugs Requiring Transmission of a Diagnosis Code
Abbreviated Criteria
Serve You Rx Prior Authorization Information and Drug List
(POS) Requirements for Selected Enzyme Replacement Therapy Agents
AHFS Pharmacologic-Therapeutic Classification System
FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
Nhs-England-Drugs-List-V14.1.Pdf
Non-Preferred Drug List (NPDL)
Prior Authorization — Premium
Enzyme Replacement Therapy
Complement Inhibitor and Enzyme/Protein Replacement Therapy
2019 Medicaid Preapproval Criteria
COMMISSION DE LA TRANSPARENCE Avis 16 Mars 2016
Routine Practice Data for the Benefit Assessment of Drugs 10 January 2020
2021 Medicaid Preapproval Criteria
Utah Medicaid Dur Report December 2017 Overview Of
DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
Issue and Citation Type: M= Main Feature; L= Literature Review; F= FDA Update; C= Correction)
Specialty Pharmacy Drug List Specialty Medications List
Erythrocyte Mediated Enzyme Replacement Therapy
Asfotase Alfa - Drugbank
UMP (Wsrxs) Preferred Drug List (PDL) 2021
November 2020
Orphan Medicinal Products with Marketing Authorisation
Annual Report 2015 Annexes